Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...
manilatimes8h
SAIHEAT to Announce SAIHEAT BASE PLAN 2029 on BIT HEAT DAY
SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...
clinicaltrialsarena22h
Intelligent gears up for FDA approval of fingerprint drug detection device
Intelligent Bio Solutions plans to file for 510(k) clearance with the US FDA in Q4 this year. Image credit: PRESSLAB / Shutterstock. US based company Intelligent Bio Solutions has released “strong ...
manilatimes22h
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada”, "the ...